Workshop on Recent Issues in Bioanalysis (WRIB) Poster Award winners 2018.

The 12th WRIB held in Philadelphia, USA in April 2018. It drew over 900 professionals representing large Pharmas, Biotechs, Contract Research Organizations and multiple regulatory agencies from around the world, from the global bioanalytical community. Bioanalysis and Bioanalysis Zone are very proud to be supporting the WRIB Poster Awards again this year, and we feature the profiles of the authors of the winning posters.

A double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [C]-basimglurant and absolute bioavailability after oral administration and concomitant intravenous microdose administration of [C]-labeled basimglurant in humans.

1. The emerging technique of employing intravenous microdose administration of an isotope tracer concomitantly with an [C]-labeled oral dose was used to characterize the disposition and absolute bioavailability of a novel metabotropic glutamate 5 (mGlu5) receptor antagonist under clinical development for major depressive disorder (MDD). 2.

Pharmacology of basimglurant (RO4917523, RG7090), a unique metabotropic glutamate receptor 5 negative allosteric modulator in clinical development for depression.

Major depressive disorder (MDD) is a serious public health burden and a leading cause of disability. Its pharmacotherapy is currently limited to modulators of monoamine neurotransmitters and second-generation antipsychotics. Recently, glutamatergic approaches for the treatment of MDD have increasingly received attention, and preclinical research suggests that metabotropic glutamate receptor 5 (mGlu5) inhibitors have antidepressant-like properties.